Hydroxychloroquine supplies back to normal as trials falter

The faltering progress of hydroxychloroquine (HCQ) as a potential treatment for COVID-19 has again been evident this week as the WHO abandoned its Solidarity Trial of the drug and the FDA revoked approval of HCQ as an emergency treatment for COVID-19. On 17 June the WHO announced that the Solidarity investigators made the decision to ...

Already a member?

Login to keep reading.

© 2021 the limbic